Business Context and Reporting Period
This Form 8-K is filed by NanoVibronix, Inc. (trading symbol: NAOV) on April 9, 2025, reporting events occurring on April 9 and April 11, 2025. The filing addresses a new material definitive agreement involving a promissory note issued by its wholly-owned subsidiary, ENvue Medical Holdings, Corp., and a regulatory update regarding Nasdaq listing compliance.
Key Financial Metrics
- Debt Issuance: A promissory note with a principal amount of $360,000 was issued on April 11, 2025.
- Interest Rate: The note bears interest at an annual rate of 8.0%, payable "in kind" (accrued interest is added to the principal).
- Maturity Date: June 11, 2025.
- Liquidity and Cash Flow: The filing does not provide specific cash flow, revenue, or profit figures. The note includes a redemption right allowing the lender to demand repayment from proceeds of any future common stock or Common Stock Equivalent issuance.
Material Changes
The primary material change is the creation of a direct financial obligation of $360,000, guaranteed by the parent company, NanoVibronix, Inc. Additionally, the company has resolved a prior compliance issue with Nasdaq regarding minimum bid price and minimum stockholder's equity requirements, transitioning from a deficiency status to a monitored compliance status.
Guidance, Outlook, and Risks
- Nasdaq Monitoring: The company is subject to a mandatory one-year panel monitor following the resolution of its listing deficiencies. If the company falls out of compliance with the minimum stockholder's equity rule again within this year, it will not be granted a cure period or a plan of compliance; instead, a Delist Determination Letter will be issued immediately.
- Default Risks: The promissory note contains customary events of default. In the event of a bankruptcy, the principal and accrued interest become immediately due and payable without notice.
- Redemption Risk: Future equity raises may be partially or fully directed to redeem this note at the lender's discretion.
Investor Verification Checklist
- Verify the full text of the Promissory Note (Exhibit 4.1) and Guaranty (Exhibit 10.1) for specific default triggers and covenants.
- Monitor the company's stock price and stockholder equity levels to ensure continued compliance with Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1) during the one-year monitoring period.
- Assess the impact of the 8% "in kind" interest accrual on the total debt burden by the June 11, 2025 maturity date.
- Review future capital raising activities to determine if proceeds will be diverted to satisfy the lender's redemption rights.